ConductScience.org, home
Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
API referenceFor AI assistants

Trial · NCT01263509

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Enrolled - Long-Term Extension StudySTARTED12.5 mg Combination Dose Group* → 12.5 mg Combination Group61
Enrolled - Long-Term Extension StudySTARTED25 mg Combination Dose Group* → 25 mg Combination Dose Group60
Enrolled - Long-Term Extension StudySTARTEDα-glucosidase Monotherapy Group* → 12.5 mg Combination Group32
Enrolled - Long-Term Extension StudySTARTEDα-glucosidase Monotherapy Group*→ 25 mg Combination Group26
Enrolled - Long-Term Extension StudyCOMPLETED12.5 mg Combination Dose Group* → 12.5 mg Combination Group61
Enrolled - Long-Term Extension StudyCOMPLETED25 mg Combination Dose Group* → 25 mg Combination Dose Group60
Enrolled - Long-Term Extension StudyCOMPLETEDα-glucosidase Monotherapy Group* → 12.5 mg Combination Group32
Enrolled - Long-Term Extension StudyCOMPLETEDα-glucosidase Monotherapy Group*→ 25 mg Combination Group26
Enrolled - Long-Term Extension StudyNOT COMPLETED12.5 mg Combination Dose Group* → 12.5 mg Combination Group0
Enrolled - Long-Term Extension StudyNOT COMPLETED25 mg Combination Dose Group* → 25 mg Combination Dose Group0
Enrolled - Long-Term Extension StudyNOT COMPLETEDα-glucosidase Monotherapy Group* → 12.5 mg Combination Group0
Enrolled - Long-Term Extension StudyNOT COMPLETEDα-glucosidase Monotherapy Group*→ 25 mg Combination Group0
Entered - Long-Term Extension StudySTARTED12.5 mg Combination Dose Group* → 12.5 mg Combination Group61
Entered - Long-Term Extension StudySTARTED25 mg Combination Dose Group* → 25 mg Combination Dose Group60
Entered - Long-Term Extension StudySTARTEDα-glucosidase Monotherapy Group* → 12.5 mg Combination Group32
Entered - Long-Term Extension StudySTARTEDα-glucosidase Monotherapy Group*→ 25 mg Combination Group26
Entered - Long-Term Extension StudyCOMPLETED12.5 mg Combination Dose Group* → 12.5 mg Combination Group53
Entered - Long-Term Extension StudyCOMPLETED25 mg Combination Dose Group* → 25 mg Combination Dose Group48
Entered - Long-Term Extension StudyCOMPLETEDα-glucosidase Monotherapy Group* → 12.5 mg Combination Group27
Entered - Long-Term Extension StudyCOMPLETEDα-glucosidase Monotherapy Group*→ 25 mg Combination Group24

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01263509/flow

API referenceFor AI assistants